Bintie Biopharma

Bintie Biopharma is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on developing next-generation cell therapies for solid tumors. The company utilizes its expertise in CAR-T and TCR-T technologies to create treatments designed to effectively penetrate and function within the immunosuppressive tumor microenvironment. Bintie's lead candidate, BT-001, is a Claudin 18.2-targeted CAR-T therapy currently undergoing clinical evaluation for gastric and pancreatic cancers. By integrating advanced genetic engineering with deep immunological insights, the company seeks to provide transformative outcomes for patients with hard-to-treat malignancies.